OA
OACC.US Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
- Market cap
- USD 142M
- P/E
- 38.2x
- P/B
- 1.33x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is OACC.US undervalued?
Graham numberOACC.US trades 50.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share fundamental analysis
No fundamental analysis for Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share yet.
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was founded in 1995 and is headquartered i…
Full company profileOaktree Acquisition Corp. III Life Sciences Class A Ordinary Share financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share annual financial statements
| Item | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|
| Income Statement | |||
| Revenue | - | 0.00 | - |
| Operating Income | -703.00 | -1.20M | -4.13M |
| EBITDA | 703K | -1.20M | -4.13M |
| Net Income | 2.66K | 7.29M | 3.39M |
| EPS | 0.00 | 0.38 | 0.18 |
| Balance Sheet | |||
| Total Assets | 195M | 203M | 208M |
| Total Liabilities | 7.75M | 8.32M | 10.9M |
| Shareholders' Equity | 188M | 195M | -9.62M |
| Cash & Short-term Investments | 1.36M | 1.43M | 1.23M |
| Total Debt | 11.8K | 11.8K | - |
| Cash Flow | |||
| Operating Cash Flow | -89.7K | -422K | -612K |
| Capital Expenditure | 3.00 | 0.00 | 0.00 |
| Free Cash Flow | -182.00 | -422K | -612K |
| Ratios | |||
| ROE | 0.0% | 3.7% | - |
| ROA | 0.0% | 3.6% | 1.6% |
| Debt to Equity | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share dividends
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share has not paid dividends in the last 2 fiscal years.
Who owns Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
- Insiders 0.14%
- Institutions 93.55%
- Public & others 6.30%
- Shares outstanding 13.3M
- Free float 13.1M
Top funds holding OACC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| PICTON Arbitrage Plus Alternative Fund F | 58.4K | 0.36% | 0.00% | Jun 2026 |
| Accelerate Arbitrage ETF | 21.6K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 15.2K | 0.09% | 0.00% | Aug 2026 |
| Special Opportunities Fund | 12.5K | 0.08% | 0.00% | Mar 2026 |
| PICTON Arbitrage Alternative Fund F | 4.20K | 0.03% | 0.00% | Jun 2026 |
Top institutions holding OACC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Cnh Partners, LLC | 1.32M | 5.39% | 0.00% | Jun 2026 |
| Fort Baker Capital Management LP | 1.11M | 4.50% | +10.54% | Jun 2026 |
| Decagon Asset Management LLP | 1.09M | 4.44% | +8.87% | Jun 2026 |
| Empyrean Capital Partners, LP | 900K | 3.66% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 862K | 3.51% | 0.00% | Jun 2026 |
| Boussard & Gavaudan Gestion SAS | 720K | 2.93% | 0.00% | Jun 2026 |
| Linden Advisors LLC | 600K | 2.44% | 0.00% | Jun 2026 |
| The Toronto-Dominion Bank | 554K | 2.25% | +11.61% | Jun 2026 |
| OZ Management LLC | 531K | 2.16% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 530K | 2.15% | 0.00% | Jun 2026 |
| Moore Capital Management, LP | 525K | 2.14% | 0.00% | Jun 2026 |
| LMR Partners LLP | 511K | 2.08% | 0.00% | Jun 2026 |
| Alberta Investment Management Corp | 500K | 2.03% | 0.00% | Jun 2026 |
| Verition Fund Managegment, LLC | 470K | 1.91% | +54.19% | Jun 2026 |
| Ghisallo Capital Management LLC | 450K | 1.83% | 0.00% | Jun 2026 |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | 450K | 1.83% | 0.00% | Jun 2026 |
| Two Sigma Investments LLC | 438K | 1.78% | 0.00% | Jun 2026 |
| Gritstone Asset Management LLC | 395K | 1.61% | 0.00% | Jun 2026 |
| Radcliffe Group Inc | 387K | 1.58% | +1.25% | Jun 2026 |
| K2 PRINCIPAL FUND LP | 366K | 1.49% | +87.36% | Jun 2026 |
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share company profile
- Company name
- Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
- Ticker
- OACC.US
- ISIN
- KYG6717R1121
- Exchange
- USA Stocks
- Listed since
- Dec 16, 2024
- Sector
- Financial Services
- Industry
- Health Care Providers & Services
- Fiscal year end
- December
- Address
- 333 South Grand Avenue, Los Angeles, CA, United States, 90071
- Phone
- 213 830 6300
About Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was founded in 1995 and is headquartered in Los Angeles, California.
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share management
3- Mr. Zaid PardesiCEO & Chairman · born 1983
- Mr. George A. MartinezCFO, Principal Accounting & Principal Financial Officer · born 1985
- Mr. Mathew M. PendoChief Operation Officer · born 1964